FILE:LIFE/LIFE-8K-20041209172159.txt.gz
EVENTS:	Other Events	Financial Statements and Exhibits
TEXT:
ITEM: Other Events
ITEM: Financial Statements and Exhibits
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
 
 
 
Section 8  Other Events
 
Item 8.01 Other Events.
 
On December 9, 2004, Invitrogen Corporation (the "") issued a press release announcing it has completed its exchange offer with respect to the Company's 2.0% Convertible Senior Notes due 2023 and the Company's 1.5% Convertible Senior Notes due 2024. The press release is attached hereto as Exhibit 99.1.
Company
 
Section 9 - Financial Statements and Exhibits
 
Item 9.01 Financial Statements and Exhibits.
 
 
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

Exhibit 99.1
 
 
Filed by Invitrogen Corporation pursuant to Rule 425
under the Securities Act of 1933, and Rule 13e-4
under the Securities Exchange Act of 1934
 
Subject Company: Invitrogen Corporation
Commission File No. 000-25317
 
 
Investor and Financial Contacts:
Adam S. Taich
Vice President, Investor Relations
(760) 603-7208
 
 
Invitrogen Corporation (Nasdaq: IVGN) announced today that it has completed its offer to exchange up to $350 million of new 2.0% senior convertible notes due 2023 (the "") for an equal principal amount of its currently outstanding 2.0% senior convertible notes due 2023 (the ""), and up to $450 million of new 1.5% senior convertible notes due 2024 (the "") for an equal principal amount of its currently outstanding 1.5% senior convertible notes due 2024 (the ""). In addition, Invitrogen will make a cash payment of $2.50 per $1,000 principal amount of notes accepted in the offer. The exchange offer expired at midnight, New York City time, on December 8, 2004.
Carlsbad, CA, December 9, 2004
New 2.0% Notes
Existing 2.0% Notes
New 1.5% Notes
Existing 1.5% Notes
 
As of the expiration of the exchange offer, approximately $301.35 million aggregate principal amount (including $10.56 million of notes tendered pursuant to the procedures for guaranteed delivery) representing approximately 86.1 percent of the outstanding principal amount of the Existing 2.0% Notes and $424.60 million aggregate principal amount (including $21.43 million of notes tendered pursuant to the procedures for guaranteed delivery) representing approximately 94.4 percent of the outstanding principal amount of the Existing 1.5% Notes have been tendered for exchange. All of the Existing 2.0% Notes and Existing 1.5% Notes that were properly tendered have been accepted for exchange. The exchange offer is expected to be consummated on December 14, 2004, following which, approximately $48.65 million aggregate principal amount of the Existing 2.0% Notes and approximately $25.40 million aggregate principal amount of the Existing 1.5% Notes will remain outstanding.
 
Investors and security holders may obtain the prospectus and other materials related to the exchange offer free of charge at the Securities and Exchange Commission's website () or through the information agent for the exchange offer, MacKenzie Partners, Inc., 105 Madison Avenue, New York, New York 10016 (telephone number: 212-929-5000 (call collect) or 800-322-2885 (U.S. toll free)). Banc of America Securities LLC is the exclusive dealer manager in connection with the exchange offer. Questions regarding the exchange offer may be directed to Banc of America Securities LLC, Equity-Linked Liability Management at 888-583-8900, x2200 (U.S. toll-free) and 212-933-2200 (call collect).
www.sec.gov
A registration statement relating to the securities to be issued in the exchange offer has been filed with the Securities and Exchange Commission and has been declared effective.
 
Safe Harbor Statement
 
Invitrogen's statements in this press release contain forward-looking statements regarding the timing of the exchange. There can be no assurance that Invitrogen will complete the exchange offer on the anticipated terms or at all. Invitrogen's ability to complete the exchange offer and Invitrogen's business are subject to the risks described in its filings with the Securities and Exchange Commission.
 


